This study provides evidence for the upregulation of RNA Pol I in breast cancer, particularly basal-like breast cancer, which is also associated with poor clinical outcomes as well as a possible synergistic interaction between targeting RNA pol I machinery using CX-5461 with p53 activator APR-246 in TNBC cell lines. The gene discussed is TP53; the disease is breast cancer.